FDA Moves to Reclassify 12 Peptides in Major Regulatory Shift Driven by RFK Jr.

Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.

Here’s What Happened

The U.S. Food and Drug Administration announced on June 18, 2026 that it will convene an advisory committee in July 2026 to review whether seven peptide injections should be approved for compounding pharmacy production. Simultaneously, the agency will remove 12 peptides from the Category 2 bulks list — a restrictive classification reserved for unapproved, high-risk substances that cannot be compounded. The moves follow sustained pressure from Health and Human Services Secretary Robert F. Kennedy Jr. and the Make America Healthy Again, also known as MAHA movement, representing the most consequential shift in peptide regulation since the FDA began tightening compounding rules under the Biden administration.

Context / Background

The regulatory framework for compounded peptides sits at the intersection of drug safety law, pharmacy practice, and the growing consumer demand for “wellness” injectables. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare customized medications using bulk drug substances — but only if those substances appear on the FDA’s approved bulks list or have a USP/NF monograph.

Under President Biden, the FDA took an increasingly restrictive stance. Between 2022 and 2024, the agency added nearly 20 peptides — including BPC-157, Thymosin Alpha-1, and AOD-9604 — to Category 2, effectively banning their use in compounding. The FDA’s Pharmacy Compounding Advisory Committee, also known as PCAC voted overwhelmingly that these substances “present significant safety risks” because most lack human clinical data. The peptide compounding industry, wellness influencers, and now the HHS Secretary himself have pushed back hard, arguing the restrictions limit patient access to promising therapies.

The Data / The Decision

Peptides under review — advisory committee — | 7 peptides to be evaluated for compounding eligibility.

Peptides being removed from Category 2 | 12 peptides reclassified to allow compounding.

Advisory committee meeting | July 2026.

Peptides previously added to Category 2 — Biden era — | ~20 peptides (2022–2024).

Key driver | HHS Secretary RFK Jr. + MAHA movement.

RFK Jr. personal involvement | Has discussed using peptides for his own injuries.

MAHA influencer involved | Gary Brecka — sells peptide formulas via website —.

Parallel action | FDA moving to remove GLP-1 drugs from 503B bulks list — separate, more restrictive action —.

Critics | Dr. Peter Lurie, also known as CSPI: “The Wild West is about to become wilder”.

Former FDA position | Most compounded peptides “present significant safety risks”.

Expert Insight

Anti-pattern: Treating this as a simple “pro-access vs. pro-safety” debate. Experienced regulatory professionals know the real strategic issue is regulatory pathway arbitrage. If peptides can reach patients through compounding pharmacies without an NDA or BLA, why would any company invest the $1–2 billion and 10–12 years required for formal drug approval? Dr. Peter Lurie’s warning — “I don’t see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market” — isn’t hypothetical. The peptide therapeutics industry, which has attracted over five billion dollars in venture funding since 2020, depends on a regulatory regime that rewards clinical development with market exclusivity.

The second-order effect most commentators miss: this reclassification doesn’t just affect wellness peptides like BPC-157. It creates a precedent for how the FDA handles the entire category of peptide drugs, including therapeutic peptides in active clinical development. A company with a Phase 2 peptide asset may now face competition from compounding pharmacies before it even reaches Phase 3 — a scenario that would fundamentally alter risk calculations for peptide biotech investors. CDMOs like Bachem and CordenPharma are watching this closely; expanded compounding could cannibalize the commercial manufacturing market they’re building capacity for.

Further Reading

• GLP-1 Peptide Therapeutics: The Complete 2026 Landscape
• Peptide CDMO Manufacturing Capacity: 2026 Outlook
• Peptide Regulatory Pathways: FDA vs EMA — A Comparative Analysis

[Natural sign-off — one sentence summary of why this matters.]

Last reviewed: June 2026. Peptide Proof Editorial Team. Source: PBS News / Associated Press